174 related articles for article (PubMed ID: 36498583)
1. The Impact of Lactobacillus Plantarum PCS26 Supplementation on the Treatment and Recurrence of Urinary Tract Infections in Children-A Pilot Study.
Meštrović Popovič K; Povalej Bržan P; Langerholc T; Marčun Varda N
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498583
[TBL] [Abstract][Full Text] [Related]
2. Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 versus placebo as a prophylaxis for recurrence urinary tract infections in children: a study protocol for a randomised controlled trial.
Daniel M; Szymanik-Grzelak H; Turczyn A; Pańczyk-Tomaszewska M
BMC Urol; 2020 Oct; 20(1):168. PubMed ID: 33097017
[TBL] [Abstract][Full Text] [Related]
3.
Daniel M; Szymanik-Grzelak H; Sierdziński J; Pańczyk-Tomaszewska M
Microorganisms; 2024 May; 12(6):. PubMed ID: 38930419
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial.
Gupta V; Mastromarino P; Garg R
Clin Infect Dis; 2024 May; 78(5):1154-1161. PubMed ID: 38084984
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Probiotic Prophylaxis After The First Febrile Urinary Tract Infection in Children With Normal Urinary Tracts.
Sadeghi-Bojd S; Naghshizadian R; Mazaheri M; Ghane Sharbaf F; Assadi F
J Pediatric Infect Dis Soc; 2020 Jul; 9(3):305-310. PubMed ID: 31100124
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of orally administration of viable and inactivated probiotic strains against murine urinary tract infection.
Van VTH; Liu ZS; Hsieh YJ; Shiu WC; Chen BY; Ku YW; Chen PW
J Food Drug Anal; 2023 Dec; 31(4):583-598. PubMed ID: 38526818
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Probiotics as Prophylaxis for Urinary Tract Infections in Premenopausal Women: A Systematic Review and Meta-Analysis.
Abdullatif VA; Sur RL; Eshaghian E; Gaura KA; Goldman B; Panchatsharam PK; Williams NJ; Abbott JE
Cureus; 2021 Oct; 13(10):e18843. PubMed ID: 34671514
[TBL] [Abstract][Full Text] [Related]
8. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection.
Stapleton AE; Au-Yeung M; Hooton TM; Fredricks DN; Roberts PL; Czaja CA; Yarova-Yarovaya Y; Fiedler T; Cox M; Stamm WE
Clin Infect Dis; 2011 May; 52(10):1212-7. PubMed ID: 21498386
[TBL] [Abstract][Full Text] [Related]
9. Non-antibiotic interventions for prevention of urinary tract infections in children: a systematic review and meta-analysis of randomized controlled trials.
Meena J; Thomas CC; Kumar J; Raut S; Hari P
Eur J Pediatr; 2021 Dec; 180(12):3535-3545. PubMed ID: 34156540
[TBL] [Abstract][Full Text] [Related]
10. Probiotic and cranberry supplementation for preventing recurrent uncomplicated urinary tract infections in premenopausal women: a controlled pilot study.
Koradia P; Kapadia S; Trivedi Y; Chanchu G; Harper A
Expert Rev Anti Infect Ther; 2019 Sep; 17(9):733-740. PubMed ID: 31516055
[No Abstract] [Full Text] [Related]
11. Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial.
Lee BB; Toh SL; Ryan S; Simpson JM; Clezy K; Bossa L; Rice SA; Marial O; Weber G; Kaur J; Boswell-Ruys C; Goodall S; Middleton J; Tudehope M; Kotsiou G
BMC Urol; 2016 Apr; 16():18. PubMed ID: 27084704
[TBL] [Abstract][Full Text] [Related]
12. Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli.
Ejrnæs K
Dan Med Bull; 2011 Apr; 58(4):B4187. PubMed ID: 21466767
[TBL] [Abstract][Full Text] [Related]
13. Interventions for primary vesicoureteric reflux.
Williams G; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD001532. PubMed ID: 30784039
[TBL] [Abstract][Full Text] [Related]
14. Strain-specific inhibition of the adherence of uropathogenic bacteria to bladder cells by probiotic Lactobacillus spp.
de Llano DG; Arroyo A; Cárdenas N; Rodríguez JM; Moreno-Arribas MV; Bartolomé B
Pathog Dis; 2017 Jun; 75(4):. PubMed ID: 28402532
[TBL] [Abstract][Full Text] [Related]
15. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review.
Barrons R; Tassone D
Clin Ther; 2008 Mar; 30(3):453-68. PubMed ID: 18405785
[TBL] [Abstract][Full Text] [Related]
16. Understanding the potential of lactobacilli in recurrent UTI prevention.
Vagios S; Hesham H; Mitchell C
Microb Pathog; 2020 Nov; 148():104544. PubMed ID: 33010368
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of commercial probiotic Lactobacillus strains against uropathogenic Escherichia coli.
Delley M; Bruttin A; Richard M; Affolter M; Rezzonico E; Brück WM
FEMS Microbiol Lett; 2015 Jul; 362(13):fnv096. PubMed ID: 26078118
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection.
Asahara T; Nomoto K; Watanuki M; Yokokura T
Antimicrob Agents Chemother; 2001 Jun; 45(6):1751-60. PubMed ID: 11353622
[TBL] [Abstract][Full Text] [Related]
19. Use of Lactobacillus spp. to prevent recurrent urinary tract infections in females.
Ng QX; Peters C; Venkatanarayanan N; Goh YY; Ho CYX; Yeo WS
Med Hypotheses; 2018 May; 114():49-54. PubMed ID: 29602464
[TBL] [Abstract][Full Text] [Related]
20. Probiotics prophylaxis in pyelonephritis infants with normal urinary tracts.
Lee SJ; Cha J; Lee JW
World J Pediatr; 2016 Nov; 12(4):425-429. PubMed ID: 27059742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
